Kamada (NASDAQ:KMDA) Stock Crosses Above 50 Day Moving Average – Here’s Why

Kamada Ltd. (NASDAQ:KMDA)’s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $6.96 and traded as high as $7.30. Kamada shares last traded at $7.24, with a volume of 64,147 shares.

Analysts Set New Price Targets

A number of equities research analysts recently commented on KMDA shares. HC Wainwright raised their price objective on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Kamada presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Kamada Stock Up 3.0%

The firm has a market cap of $416.37 million, a P/E ratio of 20.11, a price-to-earnings-growth ratio of 0.61 and a beta of 0.93. The firm’s 50-day moving average price is $6.96 and its 200 day moving average price is $7.12.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The business had revenue of $47.01 million for the quarter, compared to the consensus estimate of $154.21 million. Kamada had a net margin of 11.70% and a return on equity of 7.89%. On average, equities analysts predict that Kamada Ltd. will post 0.23 earnings per share for the current year.

Institutional Trading of Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Simplicity Wealth LLC bought a new stake in Kamada during the third quarter worth approximately $70,000. Trexquant Investment LP acquired a new position in shares of Kamada in the 1st quarter valued at $82,000. Man Group plc acquired a new stake in Kamada during the 3rd quarter worth about $199,000. Cubist Systematic Strategies LLC purchased a new position in shares of Kamada in the first quarter worth approximately $206,000. Finally, Jump Financial LLC acquired a new stake in shares of Kamada during the second quarter valued at approximately $219,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.